Back to Search
Start Over
Bayer presents detailed results from OASIS 3 phase III study of elinzanetant to treat VMS associated with menopause at 2024 TMS meeting
- Source :
- PharmaBiz. September 12, 2024
- Publication Year :
- 2024
-
Abstract
- Bayer will present detailed results from the phase III study OASIS 3, providing supporting efficacy data and sustained safety data over 52 weeks for the investigational compound elinzanetant, adding to [...]
Details
- Language :
- English
- Database :
- Gale General OneFile
- Journal :
- PharmaBiz
- Publication Type :
- Periodical
- Accession number :
- edsgcl.808424854